Key points are not available for this paper at this time.
This Phase II trial was objected to evaluate the efficacy and safety of adding fulvestrant to NCT in patients with ER+/HER2-locally advanced breast cancer (LABC).Additionally, the study aimed to investigate the association of 18 F-FES PET-CT and metabolites with efficacy. Materials and MethodsFulvestrant and EC-T regimen were given to ER+/HER2-LABC patients before surgery.At baseline, patients received 18 F-FES PET-CT scan, and plasma samples were taken for LC-MS analysis.The primary endpoint was ORR.Secondary endpoints included tpCR and safety. ResultsAmong the 36 patients enrolled, the ORR was 86.1%, the tpCR rate was 8.3%.The incidence of grade ≥3 TEAEs was 22%.The decrease in ER value in sensitive patients was larger than that in non-sensitive patients, as was Ki-67 (p<0.05).The SUVmax, SUVmean, TL-ER of 18 F-FES PET-CT in sensitive patients were significantly higher than those in non-sensitive patients (p<0.05).Moreover, these parameters were significantly correlated with MP grade and the change in ER expression before and after treatment (p<0.05).Thirteen differential expressed metabolites were identified, which were markedly enriched in 19 metabolic pathways. ConclusionThis regimen demonstrated acceptable toxicity and encouraging antitumor efficacy. 18F-FES PET-CT might serve as a tool to predict the effectiveness of this therapy.Altered metabolites or metabolic pathways might be associated with treatment response.
Shao et al. (Tue,) studied this question.